IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 395 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,305,935 | +82.1% | 132,311 | +65.6% | 0.01% | +80.0% |
Q1 2024 | $3,463,087 | -2.4% | 79,887 | +13.8% | 0.01% | -16.7% |
Q4 2023 | $3,550,043 | +20.9% | 70,173 | +8.4% | 0.01% | +20.0% |
Q3 2023 | $2,935,281 | +367.3% | 64,711 | +322.7% | 0.01% | +400.0% |
Q2 2023 | $628,188 | -61.7% | 15,310 | -66.7% | 0.00% | -66.7% |
Q1 2023 | $1,641,362 | -5.4% | 45,924 | -0.0% | 0.00% | -25.0% |
Q4 2022 | $1,735,297 | +105.4% | 45,941 | +140.2% | 0.00% | +100.0% |
Q3 2022 | $845,000 | +115.6% | 19,129 | +80.0% | 0.00% | +100.0% |
Q2 2022 | $392,000 | -3.7% | 10,626 | -3.6% | 0.00% | 0.0% |
Q1 2022 | $407,000 | +20.1% | 11,018 | -1.6% | 0.00% | 0.0% |
Q4 2021 | $339,000 | -15.5% | 11,194 | -19.8% | 0.00% | 0.0% |
Q3 2021 | $401,000 | -18.5% | 13,957 | -0.7% | 0.00% | 0.0% |
Q2 2021 | $492,000 | -64.3% | 14,052 | -48.8% | 0.00% | -66.7% |
Q1 2021 | $1,377,000 | -5.9% | 27,462 | +3.0% | 0.00% | -25.0% |
Q4 2020 | $1,463,000 | -63.5% | 26,651 | -68.7% | 0.00% | -66.7% |
Q3 2020 | $4,013,000 | -27.4% | 85,131 | -9.5% | 0.01% | -29.4% |
Q2 2020 | $5,529,000 | +29.2% | 94,051 | +3.9% | 0.02% | +6.2% |
Q1 2020 | $4,278,000 | -28.2% | 90,483 | -8.3% | 0.02% | -11.1% |
Q4 2019 | $5,962,000 | +37.9% | 98,697 | +36.8% | 0.02% | +63.6% |
Q3 2019 | $4,322,000 | -2.6% | 72,142 | +4.5% | 0.01% | -21.4% |
Q2 2019 | $4,437,000 | -18.7% | 69,041 | +2.7% | 0.01% | -22.2% |
Q1 2019 | $5,459,000 | +94.3% | 67,249 | +23.4% | 0.02% | +80.0% |
Q4 2018 | $2,810,000 | 0.0% | 54,477 | 0.0% | 0.01% | 0.0% |
Q3 2018 | $2,810,000 | -32.0% | 54,477 | -45.1% | 0.01% | -28.6% |
Q2 2018 | $4,134,000 | +24.0% | 99,205 | +31.2% | 0.01% | +7.7% |
Q1 2018 | $3,334,000 | +17.6% | 75,633 | +34.1% | 0.01% | +30.0% |
Q4 2017 | $2,836,000 | +0.1% | 56,395 | +1.0% | 0.01% | 0.0% |
Q3 2017 | $2,832,000 | +8.4% | 55,849 | +8.7% | 0.01% | 0.0% |
Q2 2017 | $2,613,000 | +61.5% | 51,357 | +27.6% | 0.01% | +42.9% |
Q1 2017 | $1,618,000 | -6.6% | 40,237 | +11.1% | 0.01% | -12.5% |
Q4 2016 | $1,732,000 | -63.1% | 36,207 | -71.7% | 0.01% | -66.7% |
Q3 2016 | $4,693,000 | +49.9% | 128,085 | -4.7% | 0.02% | +26.3% |
Q2 2016 | $3,131,000 | +85.2% | 134,430 | +222.0% | 0.02% | +72.7% |
Q1 2016 | $1,691,000 | +1116.5% | 41,754 | +1764.0% | 0.01% | +1000.0% |
Q4 2015 | $139,000 | – | 2,240 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |